Source: Internal Medicine Journal, Volume 40, Number 11, November 2010 , pp. 742-750(9)
Abstract:Malignant mesothelioma (MM) is an aggressive tumour that commonly affects the mesothelial surfaces of the pleural and peritoneal cavities, and occasionally, the tunica vaginalis and the pericardium. Formerly a rare tumour, MM is increasing in incidence in Australia due to the heavy nationwide use of asbestos from 1940 until the 1980s. The incidence is expected to peak in Australia in the next decade, mirroring the long latency period between asbestos exposure and development of MM. Diagnosis of MM can be difficult. Definitive pathological diagnosis is required and it often requires an experienced pathologist to differentiate MM from other benign or malignant processes. Treatment of MM requires a multidisciplinary approach, regardless of palliative or curative intent. Treatment options, such as surgery, chemotherapy, radiotherapy and active symptom control or a combination of these, may be used. Further research is needed to advance the therapeutic options for MM, and strategies to realize personalisation of therapy through discovery of predictive markers. In the Australian society where asbestos contamination of the built environment is very high, education and stringent public health measures are required to prevent a second wave of increased MM incidence.
Document Type: Research article
Affiliations: 1: Asbestos Diseases Research Institute (ADRI), Bernie Banton Centre and 2: Department of Anatomical Pathology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia 3: Department of Medical Oncology, Sydney Cancer Centre, Concord Repatriation General Hospital,
Publication date: 2010-11-01